Neoadjuvant chemotherapy in gynecological cancers

Neoadjuvant chemotherapy in gynecological cancers is an approach that is shown to have positive effects on survival. It increases the rate of resectability in ovarian and cervical cancers and thus contributes to survival. However, there are studies reporting that despite increasing operability, the approach does not make any changes in terms of survival. Nevertheless, no negative effects have been reported in studies conducted till today. Prospective and randomized well-designed studies that encompass a high number of cases and parameters, including cost-effectiveness, are needed in both types of cancers. Until the results of such studies are obtained, neoadjuvant chemotherapy may be taken into consideration as an alternative when conventional methods do not suffice. The number of studies concerning endometrial, vulvar and vaginal cancers are few in the area of neoadjuvant chemotherapy.

Gynecologic cancer; Chemotherapy; Neoadjuvant chemotherapy; Ovarian cancer; Cervical cancer; Vulvar cancer; Endometrial cancer

[1] Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J.: "Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis". J. Clin. Oneal., 2002, 20, 1248.

[2] Cannistra S.A.: "Cancer of the ovary". N. Engl. J. Med., 1993, 329, 1550.

[3] Memarzadeh S., Berek J.S.: "Advances in the management of epithelial ovarian cancer". J. Reprod. Med., 2001, 46,621.

[4] Jacob J.H., Gershenson D.M., Morris M., Copeland L.J., Burke T.W., Wharton J.T.: "Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer". Gynecol. Oneal., 1991, 42, 146.

[5] Mazzeo F., Berliere M., Kerger J., Squifflet J., Duck L., D'Hondt V. et. al: "Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced stage ovarian cancer". Gynecol. Oneal., 2003, 90, 163.

[6] Vrscaj M.U., Rakar S.: "Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study". Eur. J. Gynaecol. Oneal., 2002, 23, 405.

[7] Vergote I.B., De Wever I., Decloedt J., Tjalma W., Van Gramberen M., van Dam P.: "Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer". Semin. Oneal., 2000, 27, 31.

[8] Vergote I., De Wever I., Tjalma W., Van Gramberen M., Decloedt J., van Dam P.: "Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients". Gynecol. Oneal., 1998, 71, 431.

[9] Dauplat J., Le Bouedec G., Pomel C., Scherer C.: "Cytoreductive surgery for advanced stages of ovarian cancer". Semin. Surg. Oneal., 2000, 19, 42.

[10] Michel G., De Iaco P., Castaigne D., el- Hassan M.J., Lobreglio R., Lhomme C. et al.: "Extensive cytoreductive surgery in advanced ovarian carcinoma". Eur. J. Gynaecol. Oneal., 1997, 18, 9.

[11] Schwartz P.E., Rutherford T.J., Chambers J.T., Kohom E.I., Thiel R.P.: "Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival". Gynecol Oneal., 1999, 72, 93.

[12] Schwartz P.E., Chambers J.T., Makuch R.: "Neoadjuvant chemotherapy for advanced ovarian cancer". Gynecol. Oneal., 1994, 53, 33.

[13] Kuhn W., Rutke S., Spathe K., Schmalfeldt B., Florack G., von Hundelshausen B. et al.: "Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma". Cancer, 2001, 92, 2585.

[14] Ansquer Y., Leblanc E., Clough K., Morice P., Dauplat J ., Mathevet P. et al.: "Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study". Cancer, 2001, 91, 2329.

[15] Chan Y.M., Ng T.Y., Ngan H.Y., Wong L.C.: "Quality of lii£fe in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study". Gynecol. Oneal., 2003, 88, 9.

[16] Nguyen H.N., Nordqvist S.R.: "Chemotherapy of advanced and recurrent cervical carcinoma". Semin. Surg. Oneal., 1999, 16, 247.

[17] Panici P.B., Scarnbia G., Baiocchi G., Greggi S., Ragusa G., Gallo A. et al.: "Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival". Cancer, 1991, 67, 372.

[18] Namkoong S.E., Park J.S., Kim J.W. et al.: "Comparative study of the patients with locally advanced stage I and II cervical cancer treated by radical surgery with and without preoperative adjuvant chemotherapy". Gynecol. Oneal., 1995, 59, 136.

[19] Sardi J.E., Sananes C., Giaroli A.: "Results of a prospective randomized trial with neoadjuvant hemotherapy in stage IB, bulky, squamous carcinoma of the cervix". Gynecol. Oneal., 1993, 49, 156.

[20] Chang H.C., Lai C.H., Chou P.C., Tseng C.J., Chang T.C., Hsueh S. et al.: "Neoadjuvant chemotherapy with cisplatin, vincristine, and bleomycin and radical surgery in early-stage bulky cervical carcinoma". Cancer Chemother. Pharmacol., 1992, 30, 281.

[20] Napolitano U., Imperato F., Mossa B., Framarino M.L., Marziani R., Marzetti L.: "The role of neoadjuvant chemotherapyfor squamous cell cervical cancer (lb-Illb): a long-term randomized trial". Eur. J. Gynaecol. Oneal., 2003, 24, 51.

[21] Chang T.C., Lai C.H., Hong J.H., Hsueh S., Huang K.G., Chou H.H. et al.: "Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin and raidcal hysterectomy versus radiation therapy for bulky 1B and IIA cervical cancer". J. Clin. Oneal., 2000, 18, 1740.

[22] Huang H.J., Chang T.C., Hong J.H., Tseng C.J., Chou H.H., Huang K.G., Lai C.H.: "Prognostic value of age and histologic type in neoadjuvant chemotherapy plus radical surgery for bulky (>/=4 cm) stage 1B and IIA cervical carcinoma". Int. J. Gynecol. Cancer, 2003, 13, 204.

[23] Fujiwaki R., Takahashi K., Kitao M.: "Decrease in tumor volume and histologic response to intraarterial neoadjuvant chemotherapy in patients with cervical and endometrial adenocarcinoma". Gynecol. Oneal., 1997, 65, 258.

[24] Usuki N., Hirokawa K., Tashiro T., Saiwai S., Miyamoto T.: "Intraarterial chemotherapy for uterine cervical adenocarcinoma: evaluation of its efficacy as neoadjuvant therapy". Nippon Igaku Hoshasen Gakkai Zasshi, 1999, 59, 670.

[25] Homesley H.D., Bundy B.N., Sedlis A., Yordan E., Berek J.S. et al.: "Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study)". Am. J. Obstet. Gynecol., 1991, 164, 997.

[26] Salom E.M., Penalver M.: "Recurrent vulvar cancer". Curr. Treat. Options Oneal., 2002, 3, 143.

[27] Benedetti-Panici P., Greggi S., Scambia G., Salemo G., Mancuso S.: "Cisplatin (P), bleomycin (B), and methotrexate (M) preoperative chemotherapy in locally advanced vulvar carcinoma". Gynecol. Oneal., 1993, 50, 49.

[28] Wagenaar H.C., Colombo N., Vergote I., Hoctin-Boes G., Zanetta G., Pecorelli S. et al.: "Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study". European Organization for Research and Treatment of Cancer. Gynecol Oneal., 200 I, 81, 348.

[29] Levine D.A., Hoskins W.J.: "Update in the management of endometrial cancer". Cancer J., 2002, 1, 31.

[30] Taniguchi Y., Matsuo M., Umeki H., Tada M., Kohyarna A., Kuwae C. et al.: "A case of histological complete remission by preoperative intraarterial infusion chemotherapy Gan To Kagaku Ryoho", 1995, 22, 1702.

[31] Resnik E., Taxy J.B.: "Neoadjuvant chemotherapy in uterine papillary serous carcinoma". Gynecol. Oneal., 1996, 62, 123.[32] Le T.D., Yamada S.D., Rutgers J.L., DiSaia P.J.: "Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin". Gynecol. Oneal., 1999, 73, 461.

[33] Grigsby P.W.: "Vaginal cancer". Curr. Treat. Options Oneal., 2002, 3, 125.

[34] Long H.J. 3rd, Cross W.G., Wieand H.S., Webb M.J., Mailliard J.A., Kugler J.W. et al.: "Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina". Gynecol Oneal., 1995, 57, 235.

[35] Tessarolo M., Ferraris G., Re A., Leo L., Bellino R., Lauricella A., Lanza A.: "Advanced primary squamous carcinoma of the vagina treated with carboplatinum (JM 8). A case report". Eur. J. Gynaecol. Oneal., 1994, 15,230.

[36] Umesaki N., Kawamura N., Tsujimura A., Ichimura T., Tanaka T., Ogita S.: "Stage II vaginal cancer responding to chemotherapy with irinotecan and cisplatin: a case report". Oneal. Rep., 1999, 6, 123.